Douglas Mack

1 month ago | digitalcommons.library.tmc.edu | Douglas Mack |Timothy E. Dribin |Paul Turner |Richard Wasserman

BACKGROUND: Despite the promise of oral immunotherapy (OIT) to treat food allergies, this procedure is associated with potential risk. There is no current agreement about what elements should be included in the preparatory or consent process. OBJECTIVE: We developed consensus recommendations about the OIT process considerations and patient-specific factors that should be addressed before initiating OIT and developed a consensus OIT consent process and information form.

Dec 19, 2023 | tandfonline.com | David Stukus |Douglas Mack |Vivian P Hernandez-Trujillo |Hugh A. Sampson

Plain Language SummaryWhat is this summary about? This is a summary of an article published in The New England Journal of Medicine about the EPITOPE clinical study, which tested a skin patch called ViaskinTM Peanut 250 μg (micrograms) as a treatment option for peanut allergy in children aged 1 through 3 years.

Dec 19, 2023 | futuremedicine.com | David Stukus |Ruchi Gupta |Douglas Mack |Lianne Mandelbaum

This is an abstract of the Plain Language Summary of Publication article. To read the full Plain Language Summary of this article, click here to view the PDF. Link to original article hereAcknowledgmentsDBV Technologies, a biopharmaceutical company, funded this study and would like to thank the children who volunteered to participate, their families and caregivers and those who conducted the study.

Dec 19, 2023 | brnw.ch | David Stukus |Ruchi Gupta |Douglas Mack |Lianne Mandelbaum

DBV Technologies, a biopharmaceutical company, funded this study and would like to thank the children who volunteered to participate, their families and caregivers and those who conducted the study. DRS reports consulting fees from ARS Pharmaceuticals, Novartis, and Kaléo, royalties from Springer Publishing, and honoraria from the American Academy of Pediatrics and the Collegiate and Professional Sports Dietitians Association.